The 68Ga-PSMA-11 radioactive tracer has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the study of PCa in different clinical environments [45]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.